Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

Bibliographic Details
Main Authors: Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won Lee, Keun Seok Lee, Joohyuk Sohn, Kyung Hae Jung, In Hae Park
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Breast
Subjects:
HER2 positive
Metastatic breast cancer
Trastuzumab biosimilar
Clinical trial
ctDNA
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977622001333

Internet

http://www.sciencedirect.com/science/article/pii/S0960977622001333

Similar Items